WO2008027442A3 - Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use - Google Patents

Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use Download PDF

Info

Publication number
WO2008027442A3
WO2008027442A3 PCT/US2007/019015 US2007019015W WO2008027442A3 WO 2008027442 A3 WO2008027442 A3 WO 2008027442A3 US 2007019015 W US2007019015 W US 2007019015W WO 2008027442 A3 WO2008027442 A3 WO 2008027442A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid agonists
pharmaceutical formulations
oral pharmaceutical
abuse deterrent
agonists
Prior art date
Application number
PCT/US2007/019015
Other languages
French (fr)
Other versions
WO2008027442A2 (en
Inventor
Najib Babul
Original Assignee
Theraquest Biosciences Llc
Najib Babul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Llc, Najib Babul filed Critical Theraquest Biosciences Llc
Publication of WO2008027442A2 publication Critical patent/WO2008027442A2/en
Publication of WO2008027442A3 publication Critical patent/WO2008027442A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The present invention is directed to pharmaceutical compositions of opioid agonists and the use thereof for preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alcohol from either intentional or unintentional tampering. The present invention is also directed at methods of preventing or minimizing the risk of abuse and/or toxicity due to opioid agonists and any co-abused cannabinoid agonists or alcohol from either intentional or unintentional tampering.
PCT/US2007/019015 2006-08-30 2007-08-30 Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use WO2008027442A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84097006P 2006-08-30 2006-08-30
US60/840,970 2006-08-30
US84899406P 2006-10-04 2006-10-04
US60/848,994 2006-10-04

Publications (2)

Publication Number Publication Date
WO2008027442A2 WO2008027442A2 (en) 2008-03-06
WO2008027442A3 true WO2008027442A3 (en) 2008-10-16

Family

ID=39136569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019015 WO2008027442A2 (en) 2006-08-30 2007-08-30 Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use

Country Status (1)

Country Link
WO (1) WO2008027442A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
ATE495732T1 (en) 2003-03-26 2011-02-15 Egalet As CONTROLLED RELEASE MORPHINE SYSTEM
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
CA2709903A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Oral opioid compositions with opioid antagonist
WO2009085778A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20110097395A1 (en) * 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20100063148A1 (en) * 2008-09-05 2010-03-11 Gruenenthal Gmbh Pharmaceutical Combination
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
CN104257600A (en) * 2008-10-30 2015-01-07 格吕伦塔尔有限公司 Novel And Potent Tapentadol Dosage Forms
WO2010066034A1 (en) 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
DK2651415T3 (en) 2010-12-13 2020-11-30 Rite Prep Pty Ltd STOMACH AND COLOR FORMULATIONS AND METHODS FOR THE PREPARATION AND USE OF THEM
CN102210764B (en) * 2011-05-30 2013-04-17 陕西师范大学 Application of sweet almond oil in preparing medicament for treating myocardial ischemia reperfusion injury
CN102526353B (en) * 2012-03-15 2015-12-16 山东金诃药物研究开发有限公司 A kind of preparation method for the treatment of the drug combination preparation of myocardial ischemia
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
RU2015106688A (en) 2012-07-27 2016-09-20 Редхилл Байофарма Лтд. DRUGS AND METHODS FOR OBTAINING DRUGS FOR USE IN EMPTY DRAGES
CA2882316A1 (en) * 2012-08-29 2014-03-06 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
ES2675018T3 (en) 2013-02-08 2018-07-05 General Mills, Inc. Sodium Reduced Food Products
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN106535901B (en) * 2014-03-12 2020-03-31 哥伦比亚大学董事会 Mu-opioid receptor agonists
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN104324311A (en) * 2014-09-22 2015-02-04 陈英娣 Traditional Chinese medicine for treatment of multiple sclerosis
AU2015336065A1 (en) * 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN107205943A (en) * 2014-12-08 2017-09-26 德威洛克制药有限公司 Naloxone single dose and multilayer tablet
KR20180012771A (en) * 2015-05-13 2018-02-06 4피-파마 Stimulant abuse inhibiting composition
US9827282B2 (en) * 2015-07-24 2017-11-28 Bao Tran Medication dispensing system
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceuticals ingredients
CA3108216A1 (en) 2018-07-18 2020-01-23 Glatt Gmbh Immediate release formulations of cannabinoids
WO2020252284A1 (en) * 2019-06-13 2020-12-17 Imbucanna, Inc Compressible cannabinoid pharmaceutical composition
EP4034116A4 (en) * 2019-09-26 2023-10-25 The Board of Trustees of the Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
CN112759670B (en) * 2020-12-17 2022-03-15 中国石油大学(华东) Mussel bionic functionalized hydrophilic polymer and hydrophilic polymer network modified super-hydrophilic net membrane as well as preparation method and application thereof
CN113265436A (en) * 2021-06-07 2021-08-17 南京中医药大学 Method for efficient biotransformation of anthraquinone products from traditional Chinese medicine sources by using streptomyces coeruleorubidus DM

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030073714A1 (en) * 2001-08-06 2003-04-17 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US20030143269A1 (en) * 2000-02-08 2003-07-31 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US20030143269A1 (en) * 2000-02-08 2003-07-31 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030073714A1 (en) * 2001-08-06 2003-04-17 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same

Also Published As

Publication number Publication date
WO2008027442A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008027442A3 (en) Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
WO2008021394A3 (en) Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A3 (en) Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2008024408A3 (en) Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2007087452A3 (en) Abuse resistant and extended release formulations and method of use thereof
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
WO2008013838A3 (en) Pyridizinone derivatives
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
WO2008049116A3 (en) Substituted indoles
WO2007136439A3 (en) Hyperpolarization methods, systems and compositions
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
WO2007109604A3 (en) Pharmaceutical compositions
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
WO2007054623A3 (en) Mammalian hedgehog signaling inhiabitors
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2007130780A3 (en) Benzimidazole modulators of vr1
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837500

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837500

Country of ref document: EP

Kind code of ref document: A2